Wen Y Edward, Rail Benjamin, Sanchez Cristina V, Gorman April R, Rozen Shai M
Department of Plastic Surgery, University of Texas Southwestern Medical Center, Dallas, Texas.
Department of Biostatistics, University of Texas Southwestern Medical Center, Dallas, Texas.
J Reconstr Microsurg. 2025 Jul;41(6):495-507. doi: 10.1055/a-2434-4737. Epub 2024 Oct 3.
Facial paralysis due to cancer can be misdiagnosed as Bell's palsy. This study aims to clearly identify and quantify diagnostic differentiators and further evaluate the prognostic implications of misdiagnosis.
Adult patients older than 18 years with facial palsy of unknown or cancerous etiology presenting between 2009 and 2023 were reviewed. Patient characteristics, examination findings, and clinical course were compared between facial paralysis patients with cancer misdiagnosed as Bell's palsy (Cancer-Bell's-Palsy group) and patients correctly diagnosed with Bell's palsy (Bell's-Palsy group). Additionally, morbidity and mortality were compared between facial paralysis patients with cancer initially misdiagnosed with Bell's palsy and facial paralysis patients initially correctly diagnosed with cancer (Cancer-Palsy group).
Two-hundred and forty-three patients participated including 43 Cancer-Palsy, 18 Cancer-Bell's-Palsy, and 182 Bell's-Palsy patients. Cancer-Bell's-Palsy patients were significantly less likely than Bell's-Palsy patients to develop synkinesis (odds ratio [OR] = 0.0042; 95% confidence interval [CI]: [0.0005-0.0339]; < 0.0001), significantly more likely to experience gradual onset facial paralysis (OR = 1,004.69; 95% CI: [54.40-18,555.77]; < 0.0001), and significantly more likely to have additional nonfacial cranial nerve neuropathies (OR = 49.98; 95% CI: [14.61-170.98]; < 0.0001). Cancer-Bell's-Palsy patients were more likely than Cancer-Palsy patients to have a greater than 6-month period from initial cancer-attributable symptom onset to cancer diagnosis (OR = 47.62; 95% CI: [9.26-250.00]; < 0.001), stage IV cancer (OR: 12.36; 95% CI: 1.49-102.71; = 0.006), and decreased duration of life after cancer diagnosis (median [interquartile range], 40.0 [87.0] vs. 12 [56.3] months, respectively; = 0.025).
Facial paralysis related to cancer must be differentiated from Bell's palsy, as misdiagnosis leads to delayed intervention and poorer prognosis. Gradual onset facial palsy, multiple cranial nerve neuropathies, lack of synkinesis, and lack of improvement were nearly definitive differentiators for underlying cancer.
癌症导致的面瘫可能被误诊为贝尔麻痹。本研究旨在明确识别和量化诊断鉴别因素,并进一步评估误诊的预后影响。
回顾了2009年至2023年间出现病因不明或癌症性面瘫的18岁以上成年患者。比较了被误诊为贝尔麻痹的癌症性面瘫患者(癌症-贝尔麻痹组)和被正确诊断为贝尔麻痹的患者(贝尔麻痹组)的患者特征、检查结果和临床病程。此外,比较了最初被误诊为贝尔麻痹的癌症性面瘫患者和最初被正确诊断为癌症的面瘫患者(癌症-面瘫组)的发病率和死亡率。
243名患者参与了研究,包括43名癌症-面瘫患者、18名癌症-贝尔麻痹患者和182名贝尔麻痹患者。癌症-贝尔麻痹患者发生联带运动的可能性显著低于贝尔麻痹患者(优势比[OR]=0.0042;95%置信区间[CI]:[0.0005-0.0339];P<0.0001),发生渐进性面瘫的可能性显著更高(OR=1004.69;95%CI:[54.40-18555.77];P<0.0001),并且发生额外非面部颅神经病变的可能性显著更高(OR=49.98;95%CI:[14.61-170.98];P<0.0001)。癌症-贝尔麻痹患者从最初的癌症归因症状出现到癌症诊断的时间超过6个月的可能性高于癌症-面瘫患者(OR=47.62;95%CI:[9.26-250.00];P<0.001)、IV期癌症(OR:12.36;95%CI:1.49-102.71;P=0.006),并且癌症诊断后的生存期缩短(中位数[四分位间距]分别为40.0[87.0]个月和12[56.3]个月;P=0.025)。
必须将与癌症相关的面瘫与贝尔麻痹区分开来,因为误诊会导致干预延迟和预后较差。渐进性面瘫、多发性颅神经病变、无联带运动和无改善几乎是潜在癌症的确定性鉴别因素。